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AbstrACt
Objectives To assess the degree of readability and the 
length of the package leaflets of biosimilars.
setting The package leaflets analysed were downloaded 
from the European Medicines Agency (EMA) website.
Participants The study sample included the package 
leaflets written in English of all the biosimilars that were 
authorised by the EMA on 31 August 2017, and whose 
content was available via the internet on that date (n=35).
Design This was a cross-sectional analytical study. 
The readability of the package leaflets of all biosimilars 
authorised by the EMA in August 2017 was determined 
applying the Flesch and Flesch-Kincaid formulas. The 
influence of the following variables on the readability and 
length was also analysed: package leaflet section, type of 
biosimilar, date of first authorisation of the biosimilar and 
type of medicine.
results A considerable variation of the package leaflets 
length was found (3154±803). The readability of all the 
package leaflets overtook the recommended value for 
health-related written materials taking into account 
Flesch-Kincaid Index, and none of the package leaflets 
were easy to understand according to the Flesch Index. 
Statistically significant differences (p<0.05) were 
observed between the sections of package leaflets in 
readability indices and length. The most difficult sections 
to understand were those related with the therapeutic 
indication of medicine and the possible side effects.
Conclusions Package leaflets for authorised biosimilars 
may not fulfil the function for which they were designed. 
The competent organisations could be informed about 
the possible negative effect on the use of this type of 
medicines.
IntrODuCtIOn 
According to the European Medicines 
Agency (EMA), a biological product is one 
that contains one or more active substances 
derived from a biological source.1 A biosim-
ilar is  ‘a biological medicinal product that 
contains a version of the active substance 
of an already authorised original biological 
medicinal product (reference medicinal 
product) in the European Economic Area’.2 
Biosimilars have shorter clinical development 
programmes than the corresponding refer-
ence medicines,3 and undergo regulatory 
processes that make use of prior experiences 
with the reference medicines.4 The active 
substance of a biosimilar and that of its 
reference medicine are essentially the same 
biological substance, but they do have differ-
ences due to the complexity of their nature 
and the methods of production,1 which do 
not affect the safety or the effectiveness of 
the medicine.5 The aim of developing biosim-
ilar medicines was to reduce the price of the 
medicines and to promote competition in the 
pharmaceutical market.6 
Biosimilars can only be authorised once 
the period of exclusivity of the reference 
biological medicine has expired.1 In the 
European Union (EU), the first biological 
product patents expired in 2001, and it was 
not until several years later, in 2006, that the 
EMA approved the first biosimilar.7 Since 
then, EMA has pioneered the regulation of 
this type of medicinal products for human 
use.8 However, once a biosimilar has been 
approved, the policies adopted by different 
European countries with respect to the use 
of biosimilars present differences concerning 
the extent to which this type of medicinal 
product is promoted.9 There are also notable 
differences at the intercontinental level 
regarding the clinical development and use 
of biosimilars, as can be seen by comparing 
the EU and the USA.10
The existence of reliable information on 
medicines, which is up to date and can be 
accessed by patients, is vital so that the patients 
strengths and limitations of this study
 ► The study addresses a gap in the current evidence 
regarding determination of readability of biosimilar 
package leaflets in the European Union.
 ► Readability formulas can be considered as a first 
step to identify understanding problems in health-re-
lated written materials.
 ► One weakness of the study was that no patients 
were consulted. Therefore, these results could be 
complemented with direct methods of evaluation of 
readability with patients.
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can participate in shared decision-making regarding their 
treatment. This has become even more important at the 
current stage of the development of biosimilars,11 as a 
consequence of the considerable and increasing number 
of biosimilars that are now available on the market.12 
One source of information on medicines, and the most 
commonly consulted by patients, is the package leaflet,13 
which is defined as ‘a leaflet containing information for 
the user which accompanies the medicinal product’.14 
The package leaflet is crucial in the transmission of infor-
mation related to medicines to citizens, as it can help to 
complement and reinforce the information received from 
healthcare professionals,15 which in turn can increase 
adherence and, in general, suitable use of medicinal 
products. To help improve the writing of package leaflets 
and make them easy for patients to read and understand, 
in 2009, the European Commission published its ‘Guide-
line on the readability of the label and package leaflet of 
medicinal products for human use’, in which it provided 
guidance on good writing for labelling and package leaf-
lets, with the aim of making them easier to understand.16
One aspect that influences correct comprehension 
of written material is, in general, the level of literacy of 
the public.17 Therefore, health literacy influences the 
understanding of health-related written materials (which 
is precisely what package leaflets are). According to 
Nutbeam,18 ‘health literacy represents the cognitive and 
social skills which determine the motivation and ability 
of individuals to gain access to, understand and use 
information in ways which promote and maintain good 
health’. Insufficient health literacy is related to a reduc-
tion in adherence,19 and it is also considered a barrier 
that prevents people from accessing healthcare systems.20
Another aspect that should be taken into account when 
it comes to arriving at an appropriate interpretation 
of a text is its readability, which indicates how easy it is 
to understand the text, in accordance with the style of 
writing adopted.21 According to EU Directive 2004/27/
EC, ‘the package leaflet must be written and designed to 
be clear and understandable, enabling the users to act 
appropriately, when necessary with the help of health 
professionals’.22 The readability of a text can be objec-
tively measured using readability formulas, which are 
commonly used to measure the readability of different 
types of health-related written materials,23 24 many of 
which are available on the internet.25 It is recommended 
that health-related written materials do not have a level 
of readability beyond the sixth grade level (ages 11–12),26 
and this is also true of package leaflets. Meanwhile, if 
health-related written materials are excessively long, this 
could make them more difficult to understand.17
Taking into account the forecast growth in the market of 
biosimilars in the coming years,27 studying the readability 
of the package leaflets of biosimilars that are currently 
on the market is an important task. Therefore, the objec-
tive of this study was to determine and assess the degree 
of readability and the length of the package leaflets of 
all the biosimilars authorised by the EMA on 31 August 
2017, and also to study the influence of certain categor-
ical variables on these quantitative variables. We believe 
that the results will allow us to assess the suitability of the 
writing of package leaflets with regards to the needs of 
the patient, and if it is found not to meet those needs, to 
warn of the possible need to modify the contents.
MethODs
study type, selection criteria and source of the sample
We designed a cross-sectional analytical study. The study 
sample included the package leaflets written in English 
of all the biosimilars that were authorised by the EMA on 
31 August 2017, and whose content was available via the 
internet on that date (n=35). These package leaflets were 
downloaded from the EMA website,28 on 31 August 2017.
Patient and public involvement
Patients and/or public were not involved.
sample characteristics
The biosimilars studied (n=35) included human growth 
hormones, insulins, granulocyte-colony stimulating 
factors, erythropoietins, follitropins29 and, since more 
recently, low-molecular-weight heparins, parathyroid 
hormones and monoclonal antibodies (table 1).
Five of the six sections that commonly make up package 
leaflets were studied30: ‘1. What X is and what it is used 
for’ (n=35), ‘2. What you need to know before you<take> 
<use> X’ (n=35), ‘3. How to <take> <use> X’ (n=35), 
‘4. Possible side effects’ (n=35) and ‘5. How to store X’ 
(n=35). We excluded section ‘6. Contents of the pack and 
other information’ as it was similar for all the package 
leaflets and, moreover, the content of this section is not 
considered very important by the patient.31 We also eval-
uate the ‘Annex’ in those package leaflets which had one 
(n=16), which includes useful handling instructions for 
the patient.
The sections of the package leaflets to be evaluated 
were copied without any format into individual Micro-
soft Word 2013 (Microsoft Corporation) documents, 
and before calculating the quantitative variables, the 
following modifications were performed, according to 
instructions of authors’ formulas. In this way, we deleted 
all titles, subtitles, tables and their headings, graphics, 
images, figure legends and references, as well as the 
commercial name of the medicinal product and all bullet 
points (hyphens, numbers, asterisks, etc); all abbrevia-
tions, units, magnitudes and numbers were replaced by 
their meaning in words; acronyms were also replaced by 
their meaning if it had already appeared in the text; if it 
had not, then they were replaced by the transcription of 
the letters.
Figure 1 shows an example of the modifications carried 
out on the texts (package leaflets) prior to determining 
the values of the quantitative variables.
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Table 1 Biosimilars studied (n=35)
Name
Active 
substance
Biosimilar 
group
Date of 
authorisation Therapeutic area
Abasaglar Insulin glargine Hor 09/09/2014 Diabetes mellitus
Abseamed Epoetin alfa EPO 28/08/2007 Anaemia/Cancer/Chronic kidney failure
Accofil Filgrastim G-CSF 18/09/2014 Neutropaenia
Amgevita Adalimumab mAb 22/03/2017 Juvenile rheumatoid arthritis/Psoriatic arthritis/
Rheumatoid arthritis/Ulcerative colitis/Crohn’s disease/
Psoriasis/Ankylosing spondylitis
Bemfola Follitropin alfa Hor 27/03/2014 Anovulation
Benepali Etanercept TNFi 14/01/2016 Psoriatic arthritis/Rheumatoid arthritis/Psoriasis
Binocrit Epoetin alfa EPO 28/08/2007 Anaemia/Chronic kidney failure
Blitzima Rituximab mAb 13/07/2017 B-cell chronic lymphocytic leukaemia/non-Hodgkin’s 
lymphoma
Epoetin Alfa Hexal Epoetin alfa EPO 28/08/2007 Anaemia/Cancer/Chronic kidney failure
Erelzi Etanercept TNFi 23/06/2017 Juvenile rheumatoid arthritis/Psoriatic arthritis/
Rheumatoid arthritis/Psoriasis/Ankylosing spondylitis
Filgrastim Hexal Filgrastim G-CSF 06/02/2009 Cancer/Haematopoietic stem cell transplantation/
Neutropaenia
Flixabi Infliximab mAb 26/05/2016 Psoriatic arthritis/Rheumatoid arthritis/Ulcerative colitis/
Crohn’s disease/Psoriasis/ Ankylosing spondylitis
Grastofil Filgrastim G-CSF 18/10/2013 Neutropaenia
Imraldi Adalimumab mAb 24/08/2017 Arthritis/Psoriatic arthritis/Rheumatoid arthritis/
Ulcerative colitis/Crohn’s disease/
Hidradenitis suppurativa/Psoriasis/
Ankylosing spondylitis/Uveitis
Inflectra Infliximab mAb 10/09/2013 Psoriatic arthritis/Rheumatoid arthritis/Ulcerative colitis/
Crohn’s disease/Psoriasis/ Ankylosing spondylitis
Inhixa Enoxaparin 
sodium
Hep 15/09/2016 Venous thromboembolism
Lusduna Insulin glargine Hor 04/01/2017 Diabetes mellitus
Movymia Teriparatide Hor 11/01/2017 Osteoporosis
Nivestim Filgrastim G-CSF 08/06/2010 Cancer/Haematopoietic stem cell transplantation/
Neutropaenia
Omnitrope Somatropin Hor 12/04/2006 Pituitary dwarfism/Prader Willi syndrome/Turner syndrome
Ovaleap Follitropin alfa Hor 27/09/2013 Anovulation
Ratiograstim Filgrastim G-CSF 15/09/2008 Cancer/Haematopoietic stem cell transplantation/
Neutropaenia
Remsima Infliximab mAb 10/09/2013 Psoriatic arthritis/Rheumatoid arthritis/Ulcerative colitis/
Crohn’s disease/Psoriasis/Ankylosing spondylitis
Retacrit Epoetin zeta EPO 18/12/2007 Anaemia/Autologous blood transfusion/Cancer/Chronic 
kidney failure
Ritemvia Rituximab mAb 13/07/2017 non-Hodgkin’s lymphoma/Microscopic polyangiitis/
Wegener’s granulomatosis
Rituzena Rituximab mAb 13/07/2017 B-cell chronic lymphocytic leukaemia/non-Hodgkin’s 
lymphoma/Microscopic polyangiitis/Wegener’s 
granulomatosis
Rixathon Rituximab mAb 15/06/2017 Rheumatoid arthritis/B-cell chronic lymphocytic 
leukaemia/non-Hodgkin’s lymphoma/
Microscopic polyangiitis/Wegener’s granulomatosis
Riximyo Rituximab mAb 15/06/2017 Rheumatoid arthritis/non-Hodgkin’s lymphoma/
Microscopic polyangiitis/Wegener’s granulomatosis
Continued
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Quantitative variables
From the sections of the package leaflets, we deter-
mined the length of the texts (total number of words), 
and the readability as established by two indices: the 
Flesch Index32 and the Flesch-Kincaid Index.33 These 
two readability indices were chosen taking into account 
the following criteria: (1) the Flesch and Flesch-Kin-
caid formulas are the most commonly used in the liter-
ature related to health34; and (2) the two numerical 
values obtained using these formulas require different 
Name
Active 
substance
Biosimilar 
group
Date of 
authorisation Therapeutic area
Silapo Epoetin zeta EPO 18/12/2007 Anaemia/Autologous blood transfusion/Cancer/Chronic 
kidney failure
Solymbic Adalimumab mAb 22/03/2017 Psoriatic arthritis/Rheumatoid arthritis/Ulcerative colitis/
Crohn’s disease/Hidradenitis suppurativa/Psoriasis/
Ankylosing spondylitis
Terrosa Teriparatide Hor 04/01/2017 Osteoporosis
Tevagrastim Filgrastim G-CSF 15/09/2008 Cancer/Haematopoietic stem cell transplantation/
Neutropaenia
Thorinane Enoxaparin 
sodium
Hep 15/09/2016 Venous thromboembolism
Truxima Rituximab mAb 17/02/2017 Rheumatoid arthritis/B-cell chronic lymphocytic 
leukaemia/non-Hodgkin’s lymphoma/
Microscopic polyangiitis/Wegener’s granulomatosis
Zarzio Filgrastim G-CSF 06/02/2009 Cancer/Haematopoietic stem cell transplantation/
Neutropaenia
EPO, erythropoietins; G-CSF, granulocyte-colony stimulating factors; Hep, heparins; Hor, hormones; mAb, monoclonal antibodies; TNFi, 
tumour necrosis factor alpha inhibitors.
Table 1 Continued 
Figure 1 Example of modifications that were made in the evaluated sections of the package leaflets before calculating 
quantitative variables.
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interpretations, which can help with cross-checking the 
results.
The Flesch-Kincaid Index (FKGL or in full Flesch-Kin-
caid Grade Level) indicates the educational level required 
to understand a text,33 given as the number of years of 
education after the age of 6. For example, an FKGL of 
6 indicates that the reading level is equivalent to age 11 
to 12, while an FKGL of 7 indicates a reading level equiv-
alent to age 12 to 13, and so on. In contrast, the Flesch 
Index (FRE or in full Flesch Reading Ease) indicates how 
easy a text is to read, and relates the value obtained with 
the following qualitative evaluation of the text: 90–100, 
very easy; 80–90, easy; 70–80, fairly easy; 60–70, standard; 
50–60, fairly difficult; 30–50, difficult; and 0–30, very diffi-
cult.32 As can be seen, the two readability indices consid-
ered are inversely proportional: as a text becomes easier 
to read, the FKGL value goes down and the FRE goes up.
We also considered it advisable to assess the length of 
the texts, given that it has been shown that the longer a 
package leaflet, the more difficult it is to find informa-
tion, the less motivated the patient feels to read it and the 
less confident the patient feels regarding the use of the 
medicine, after having read it.35
The three quantitative variables (length, FKGL and 
FRE) were determined directly using the Microsoft Word 
2013 ‘readability statistics’ tool (Microsoft Corporation).
Qualitative variables
The influence of the following qualitative variables on 
the length and readability of the package leaflets was also 
studied.
1. Section of package leaflet: ‘1. What X is and what it is 
used for’ (n=35), ‘2. What you need to know before 
you<take> <use> X’ (n=35), ‘3. How to <take> <use> 
X’ (n=35), ‘4. Possible side effects’ (n=35), ‘5. How to 
store X’ (n=35) and ‘Annex’ (n=16).
2. Type of biosimilar, establishing six groups (table 1): 
erythropoietins (n=5), granulocyte-colony stimulating 
factors (n=7), heparins (n=2), hormones (n=7), mono-
clonal antibodies (n=12) and tumour necrosis factor 
alpha inhibitors (n=2).
3. Date of the first authorisation of the biosimilar, estab-
lishing two values for the variable: biosimilars first au-
thorised in 2006–2014 (n=18); and those authorised 
in 2015–2017 (n=17). This chosen cut-off (2014–2015) 
was because no statistically significant differences in 
the readability of package leaflets of biological med-
icines were observed in a previous longitudinal re-
search between 2007 and 2013, despite the European 
guidance of readability published in 2009.36
4. Type of medicine, establishing two values of this vari-
able: biosimilars (n=35) and their respective reference 
medicines (n=7). In this case, we only included those 
active substances whose package leaflets were available 
online from the EMA website.
For the first qualitative variable (package leaflet 
section), we considered the values of the quantitative vari-
ables (length and readability indices) obtained directly. 
However, for the other qualitative variables, in order to 
have a single value per package leaflet of each quantita-
tive variable, we considered the average values calculated 
from the values obtained in the individual sections, in the 
case of the readability indices, and the total, in the case 
of length. In addition, in the last comparative study, the 
average of the biosimilars with the same active substance 
was calculated for each quantitative variable to obtain a 
single value per active substance.
statistical analysis
Statistical calculations were performed and graphics were 
designed using the software Deducer (R V.3:15:0). We 
applied the Shapiro-Wilk test of normality to all the groups of 
values. Taking into account the normality results, we applied 
non-parametric hypothesis tests in all the comparative studies 
in which each quantitative variable was studied as a function 
of the qualitative variables. We used the Kruskal-Wallis test to 
compare the different sections of the package leaflet and the 
types of biosimilars; the Mann-Whitney U test in the compar-
ative study of the date of first authorisation of the biosimilar; 
and the Wilcoxon signed-rank test to contrast the biosimilars 
with their reference medicine. In all the hypothesis tests, we 
considered a level of significance of 0.05 when accepting or 
rejecting the null hypothesis.
results
Table 2 shows the main descriptive statistics of the three 
quantitative variables for each package leaflets analysed. 
A large variation can be seen in the total length of the 
package leaflets (3154±803). Taking into account the 
Flesch Index, none was easy of understand (all the aver-
ages were below 70). Furthermore, according to the 
Flesch-Kincaid Index, all the package leaflets were more 
difficult to read than is recommended for health-related 
texts (all the averages were over 6).
In relation to the comparative study of the quantita-
tive variables as a function of the section of the package 
leaflet, figure 2 and table 3 show descriptive statistics of 
each section. When we applied the Kruskal-Wallis test, 
we observed statistically significant differences (p<0.05) 
between the six sections in all three quantitative variables 
(length, Flesch Index and Flesch-Kincaid Index). These 
differences appeared between pairs of sections when 
we applied post hoc pairwise comparisons. The results 
show the following decreasing order for the length of the 
sections of the package leaflets of the biosimilars, from 
longest section to shortest: ‘4. Possible side effects’ > ‘3. 
How to <take> <use> X’ > ‘2. What you need to know 
before you<take> <use> X’ > ‘Annex’ > ‘1. What X is 
and what it is used for’ > ‘5. How to store X’. In terms 
of the readability of the respective sections, the following 
decreasing order of readability was observed, from the 
section that was most easy to understand to the most diffi-
cult: ‘Annex’ > ‘5. How to store X’ > ‘3. How to <take> 
<use> X’ > ‘2. What you need to know before you<take> 
<use> X’ > ‘4. Possible side effects’ > ‘1. What X is and 
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what it is used for’. In addition, taking into account the 
central values for each section, none of them was easy to 
understand, according to the qualitative scale established 
for the Flesch Index, as they all had values below 70: the 
Annex and sections 3 and 5 were standard; section 2 was 
fairly difficult; and sections 1 and 4 were difficult.
In the comparative study of the six types of biosimilars 
(erythropoietins, granulocyte-colony stimulating factors, 
heparins, hormones, monoclonal antibodies and tumour 
necrosis factor alpha inhibitors), we observed descriptive 
differences between them in terms of all three of the quan-
titative variables (figure 2 and table 4). For the length of 
the package leaflets, the following decreasing order was 
established, from the type of biosimilars with the longest 
package leaflet to the shortest: tumour necrosis factor 
alpha inhibitors>heparins> monoclonal antibodies>eryth-
ropoietins>hormones>granulocyte-colony stimulating 
factors. In terms of readability, heparins were the biosim-
ilars with the easiest package leaflets to understand, and 
tumour necrosis factor alpha inhibitors were those with 
the most difficult. In the subsequent hypothesis tests, 
we did not include the heparins or the tumour necrosis 
factor alpha inhibitors, as the samples of these types of 
biosimilars were too small for the results to be statistically 
meaningful (n=2). Taking into account this exclusion, 
the descriptive differences observed previously were not 
statistically significant (p>0.05).
When we compared the quantitative variables relative 
to the date of first authorisation of the biosimilars, there 
were no statistically significant differences (p>0.05) in 
any of the three, between the biosimilars authorised in 
the period 2006–2014 (n=18) and those authorised later 
(n=17). Despite this, we did observe a slight decrease over 
time, both in the length of the package leaflets and in 
their readability (figure 3).
Finally, when we compared the biosimilars with their 
reference medicines, we observed no statistically signifi-
cant differences (p>0.05) in any of the three quantitative 
variables, since the descriptive statistics were practically 
the same for the two groups.
DIsCussIOn
The objective of the present study was to determine the 
length and the readability of the package leaflets of the 
biosimilars authorised by the EMA. In 2017, the number 
of authorised biosimilars in Europe was growing more 
quickly than in previous years,28 and, in addition, the rate 
at which they are prescribed is also increasing compared 
with their reference medicines.37
Our results show that the package leaflets analysed are 
longer than those of non-biological medicines,35 and of 
non-biosimilar biological medicines.36 Excessive informa-
tion in the package leaflets does not meet the require-
ments of patients.17 This becomes more important for 
biosimilars, the majority of which are prescribed in the 
treatment of serious diseases, such as cancer,38 as patients 
suffering from these conditions may experience a high 
degree of anxiety from the moment they receive the 
diagnosis.39
None of the package leaflets analysed was easy to under-
stand, and the readability level of each package leaflet 
was higher than is recommended for health-related 
written materials. These results, therefore, do not comply 
Table 2 Length and readability indexes by package leaflet 
(n=35)
Name
Length FRE FKGL
Total Mean (SD) Mean (SD)
Abasaglar 3760 55.7 (18.7) 9.3 (3.3)
Abseamed 3107 57.3 (10.2) 9.1 (2.4)
Accofil 3159 51.7 (14.9) 10.8 (3.4)
Amgevita 4912 48.1 (17.0) 10.0 (3.2)
Bemfola 2973 46.1 (19.3) 11.0 (4.1)
Benepali 3790 52.6 (11.1) 9.7 (2.2)
Binocrit 3109 57.5 (10.3) 9.0 (2.3)
Blitzima 2226 54.9 (14.3) 9.6 (3.0)
Epoetin Alfa 
Hexal
3094 57.7 (10.5) 9.0 (2.3)
Erelzi 4091 50.8 (10.3) 10.1 (1.9)
Filgrastim 
Hexal
2506 57.1 (12.0) 9.4 (2.6)
Flixabi 3380 54.4 (11.6) 10.0 (3.2)
Grastofil 3167 56.1 (12.7) 9.6 (2.7)
Imraldi 4905 50.3 (14.6) 9.7 (2.7)
Inflectra 3471 54.1 (11.6) 10.2 (3.2)
Inhixa 3468 63.8 (6.2) 7.5 (1.2)
Lusduna 3608 56.2 (17.9) 9.1 (3.2)
Movymia 1798 58.0 (12.1) 8.7 (2.0)
Nivestim 2887 57.4 (12.6) 9.4 (2.8)
Omnitrope 3055 56.4 (7.4) 9.0 (1.8)
Ovaleap 2643 42.7 (20.2) 11.5 (3.9)
Ratiograstim 2581 60.3 (8.8) 8.0 (1.4)
Remsima 3438 52.2 (15.2) 10.9 (4.7)
Retacrit 4862 48.9 (17.3) 10.7 (3.7)
Ritemvia 2115 56.0 (13.9) 9.4 (3.0)
Rituzena 2195 54.5 (14.1) 9.6 (3.0)
Rixathon 2842 55.2 (13.3) 9.6 (3.2)
Riximyo 2707 56.4 (12.5) 9.5 (3.1)
Silapo 3276 47.5 (15.6) 11.0 (3.5)
Solymbic 4801 48.8 (15.7) 9.9 (3.0)
Terrosa 1795 57.9 (12.1) 8.7 (2.0)
Tevagrastim 2576 60.3 (8.8) 8.0 (1.4)
Thorinane 2849 63.2 (5.9) 7.6 (1.2)
Truxima 2752 55.1 (14.6) 9.7 (3.4)
Zarzio 2502 56.4 (13.6) 9.7 (3.3)
FKGL, Flesch-Kincaid Grade Level; FRE, Flesch Reading Ease.
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with the European regulations, according to which the 
package leaflet must be easy to read.22 The two readability 
formulas used in the present study include the length of 
the words (number of syllables per word) and the length 
of the sentences (number of words per sentence) as 
variables. These two factors are referred to in the guide-
line published by the European Commission, where 
the use of words with few syllables and short sentences 
is recommended, in order to facilitate understanding 
of the package leaflet.16 So our results show that these 
recommendations were not followed either, and in this 
they coincide with the results of a study of the readability 
of non-biosimilar biological medicines.25 These results 
were also similar to those reported from other studies 
that used the same formulas with different health-related 
written materials, such as patient information leaflets for 
health procedures,40 discharges summaries41 and also 
online materials.42
The lack of readability that the package leaflets may 
exhibit could lead to not all patients reading them, and 
even to a certain degree of alarm in patients who do read 
them, which could reduce adherence to the treatment.43 
In contrast, it has been demonstrated that written mate-
rials addressed to patients that are easily understood by 
them improve doctor–patient relations, and complement 
the information provided during visits.44 These findings 
agree with the results reported by Burgers et al,45 who 
found that patients thought it necessary to write package 
leaflets in a language that is easier to understand. It there-
fore seems clear that the package leaflet should provide 
all patients with sufficient confidence in the medicine 
to enhance a correct use, but they may not be doing 
so. By shortening the length of the text in package leaf-
lets and increasing their readability, according to the 
recommendations in the 2009 European Commission 
guideline, this situation could be improved.
When we compared the different sections of the 
package leaflets, we observed differences between them 
in both length and readability. The most difficult section 
to understand was section 1 (‘What X is and what it is 
used for’), which offers information on the therapeutic 
indications and is considered the most important by 
patients.31 Section 4 (‘Possible side effects’) was the 
second most difficult section and, despite being judged 
to be very important by patients,46 it usually contains lists 
of complex medical terms,47 which was the case in the 
majority of the package leaflets analysed in the present 
study. This can cause negative attitudes in patients when 
they are considering using the medicine, which seems to 
make it clear that this section needs to be written using a 
language which is less alarming for the patient.48 On the 
other hand, the information has to be truthful and accu-
rate according to updated evidence.28
The most easy section to understand was the Annex, 
which contains information concerning how to handle 
the device that is used to administer the medicine, 
followed by section 5 (‘How to store X’), which explains 
how the medicine should be kept. On the other hand, the 
longest sections were the warning concerning possible 
side effects, the dosing instructions, how to handle admin-
istration devices and the contraindications, results which 
were similar to those of Fuchs et al.35
In relation to the type of biosimilar, the readability of 
the heparin package leaflets was notable since, according 
to the FRE scale, they were classified as standard, whereas 
all the other types of biosimilars were classified as less 
readable according to this scale. In fact, heparins were 
the only one of the groups in which all the medicines are 
Figure 2 Box plots of quantitative variables taking into account the package leaflet section and the type of medicine.
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prescribed within the area of primary healthcare. Notwith-
standing this initial finding, our observation needs to be 
corroborated in larger samples.
We did observe that the more recently authorised 
biosimilars had shorter package leaflets, although this 
did not lead to greater readability. Based on this result, it 
would be possible to conclude that the length of the texts 
is not necessarily related to how easy they are to under-
stand. Such a conclusion would agree with the results 
of Piñero et al,36 who found no statistically significant 
correlation between the length of package leaflets and 
the results of applying the readability formulas to them.
In addition, the difficulty in understanding the package 
leaflets was independent of whether we were dealing with 
the biosimilar medicinal product or the reference medi-
cine. Therefore, patients’ need for information continues 
to be an issue for both types of medicines: biosimilars 
as well as the original reference medicines. Regulatory 
bodies and the majority of the literature on biosimilars 
focus on aspects such as safety, efficiency, quality and 
cost; so patient information continues to be undervalued 
and therefore so is the empowering of patients within a 
context of healthcare decision-making.
In this study, no patients were consulted and this could 
be a limitation. However, these formulas can be considered 
as a first step to identify readability problems independently 
of the patients. Besides, the applied readability formulas 
can predict objectively the understanding level of package 
leaflets. In this way, different studies have obtained a consis-
tency between the results obtained by applying readability 
formulas and those using user testing.49
Another limitation was package leaflet is not the only 
written source of information related the medicines. 
There are also other patient information leaflets devel-
oped by many clinicians to aim an adequate under-
standing of the information by patient.50 Nevertheless, 
most people use the internet as their first source of health 
information. In this sense, package leaflets evaluated are 
accessible online in the EMA website, independently of 
administration healthcare setting.
Table 3 Descriptive statistics of length and readability indexes by package leaflet section
Variable Package leaflet section n Median Q1–Q3 Min–Max P value*
Length
<0.001
1. What X is and what it is used for 35 222 160–326 58–829
2. What you need to know before you <take> 
<use> X
35 690 558–1180 366–1573
3. How to <take> <use> X 35 724 294–1036 199–2682
4. Possible side effects 35 817 547–1030 371–1420
5. How to store X 35 164 117–193 92–288
Annex 16 678 339–794 318–1363
FRE
<0.001
1. What X is and what it is used for 35 41.3 35.8–51.1 14.6–70.0
2. What you need to know before you <take> 
<use> X
35 54.0 45.9–60.6 34.5–66.4
3. How to <take> <use> X 35 62.0 57.0–66.0 30.9–68.4
4. Possible side effects 35 46.3 37.9–51.1 27.7–64.7
5. How to store X 35 65.1 63.0–67.4 56.0–73.9
Annex 16 69.4 65.8–71.2 64.1–78.8
FKGL
<0.001
1. What X is and what it is used for 35 11.2 9.5–13.1 6.3–17.4
2. What you need to know before you <take> 
<use> X
35 9.6 8.6–11.5 7.2–14.0
3. How to <take> <use> X 35 7.9 7.5–9.2 7.1–13.1
4. Possible side effects 35 10.7 8.5–14.5 6.9–19.0
5. How to store X 35 7.3 6.8–7.9 6.1–8.8
Annex 16 6.6 6.1–7.1 5.3–7.8
*Kruskal-Wallis test.
FKGL, Flesch-Kincaid Grade Level; FRE, Flesch Reading Ease; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
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COnClusIOn
The European Commission has made efforts to 
contribute to suitable writing of package leaflets, through 
the publication of its guideline in 2009. The marketing 
authorisation holders of biosimilars, medicines which 
have been authorised more recently than others, should 
have implemented those recommendations to a greater 
degree, as most of them were authorised in the EU after 
2009. To that end, it would always be possible, before 
publication of the package leaflet, to perform readability 
tests directly with the target patients (as is recommended 
in the guideline), and to apply readability formulas and 
assess the results as a prior step. Finally, the competent 
organisations could be informed about package leaflets 
for authorised biosimilar medicines may not fulfil the 
function for which they were designed, which could have 
Table 4 Descriptive statistics of length and readability indexes by type of biosimilar
Variable Type of medicine n Median Q1–Q3 Min–Max P value*
Length
>0.05
EPO 5 3109 3107–3276 3094–4862
G-CSF 7 2581 2541–3023 2502–3167
Hep 2 3159 3004–3313 2849–3468
Hor 7 2973 2221–3332 1795–3760
mAb 12 3111 2587–3804 2115–4912
TNFi 2 3941 3865–4016 3790–4091
FRE
>0.05
EPO 5 57.3 48.9–57.5 47.5–57.7
G-CSF 7 57.1 56.2–58.8 51.7–60.3
Hep 2 63.5 63.3–63.6 63.2–63.8
Hor 7 56.2 50.9–57.2 42.7–58.0
mAb 12 54.4 51.7–55.2 48.1–56.4
TNFi 2 51.7 51.2–52.1 50.8–52.6
FKGL
>0.05
EPO 5 9.1 9.0–10.7 9.0–11.0
G-CSF 7 9.4 8.7–9.7 8.0–10.8
Hep 2 7.5 7.5–7.6 7.5–7.6
Hor 7 9.1 8.9–10.1 8.7–11.5
mAb 12 9.7 9.6–10.0 9.4–10.9
TNFi 2 9.9 9.8–10.0 9.7–10.1
*Kruskal-Wallis test (heparins and tumour necrosis factor alpha inhibitors were excluded of the hypothesis test).
EPO, erythropoietins; FKGL, Flesch-Kincaid Grade Level; FRE, Flesch Reading Ease; G-CSF, granulocyte-colony stimulating factors; Hep, 
heparins; Hor, hormones; mAb, monoclonal antibodies; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; TNFi, tumour 
necrosis factor alpha inhibitors.
Figure 3 Medians of the quantitative variables taking into account the date of first authorisation.
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a negative effect on the use of the medicines by the user 
or patient.
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